Jami Saloman, PhD


Jami Saloman

PhD – University of Maryland (2012)
B.A. – Boston University (2006)

Office: E1457 BSTWR
200 Lothrop Street,
Pittsburgh, PA 15261

Phone: 412-648-9568
Fax: 412-648-1441
E-mail: jls354@pitt.edu

Research Interests:

Although my undergraduate research explored language perception in human subjects, my training has been largely in the fields of basic neuroscience and pain neurobiology. My graduate training focused on channel-channel and channel-receptor interactions involved in the development of masseter hypersensitivity as well as analgesia. My current interests involve exploring how communication between neurons, immune cells, and their target organs not only regulate homeostasis but also how these interactions drive the development of pathophysiological states. My main research program employs a mouse model of human pancreatic ductal adenocarcinoma (PDAC) to study the role of the nervous system in cancer, both with respect to pain and neurogenic inflammation as well as tumorigenesis itself. Our most recent studies focus on how denervation of the pancreas can slow or halt development of tumors. We are currently interested in elucidating the mechanisms underlying the efficacy of denervation. Toward this end, we are investigating whether denervation regulates the immune system, which is known to be dysregulated throughout PDAC progression.

Other research programs I am involved with explore normal function of sensory afferents and how afferent function changes with injury or inflammation. Toward this end, we have utilized anatomical, behavioral, optogenetic, chemogenetic, calcium imaging and electrophysiological techniques to identify underlying mechanisms driving pain, neurogenic inflammation and cancer.


Refereed articles

  1. Saloman JL, Albers KM, Hartman DJ, Li D, Crawford HC, Muha EA, Rhim AD, and Davis BM. Ablation of sensory neurons in a genetic model of pancreatic ductal adenocarcinoma slows initiation and progression of tumorigenesis. PNAS 2016; 113(11): 3078-3083;PMID: 26929329
  2. Saloman JL, Albers KM, Rhim AD, and Davis BM. Can Stopping Nerves Stop Cancer? Trends in Neuroscience 2016; PMID: 27832915
  3. Saloman JL, Singhi AD, Hartman DJ, Normolle DP, Albers KM, and Davis BM. Systemic depletion of nerve growth factor inhibits disease progression in a genetically engineered model of pancreatic ductal adenocarcinoma. Pancreas 2018; in press
  4. Saloman JL, Scheff NN, Snyder LM, Ross SE, Gold MS, and Davis BM. DREADD as a chemogenetic tool to suppress nociception. J Neurosci 2016; 36 (42) 10769-10781; PMID: 27798132

pubmed search for “saloman jl”